NDAORALSYRUP1 Generic Approved
Approved
Jan 1965
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Mestinon (pyridostigmine bromide) is an oral acetylcholinesterase inhibitor used to treat myasthenia gravis and other neuromuscular conditions. It works by preventing the breakdown of acetylcholine, thereby enhancing neuromuscular transmission. The drug has been a foundational therapy in neurology for nearly 60 years.
$0.007BPart D
LOE ApproachingProduct faces imminent loss of exclusivity with moderate competitive pressure (45%), signaling potential workforce reductions or redeployment on the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Mestinon roles focus on defending market share against generics and managing the transition to post-LOE revenue models. Career growth is limited; positions are typically maintenance-focused with emphasis on cost management and market access.
Brand Manager
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.